Mainz Biomed Provides Year-End Corporate Review 2023
Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
- Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
- During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
- Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
- During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.